Lenalidomide in the Treatment of Young Patients with Multiple Myeloma: From Induction to Consolidation/Maintenance Therapy
Multiple myeloma is the second most common hematologic malignancy. It accounts for 20,580 new cancer cases in the USA in 2009, including 11,680 cases in men, 8,900 cases in women, and 10,580 deaths overall. Although the disease remains still incurable, outcomes have improved substantially over recen...
Saved in:
| Main Authors: | Barbara Lupo, Antonio Palumbo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/906247 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
by: Anna Marina Liberati, et al.
Published: (2013-01-01) -
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01) -
IMPACT OF LENALIDOMIDE MAINTENANCE DOSAGE ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA
by: Zeynep Kürüm, et al.
Published: (2025-07-01) -
SARS-CoV-2 immune responses in patients with multiple myeloma and lenalidomide maintenance therapy
by: Ioana Martac, et al.
Published: (2024-12-01) -
Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)